In a report released today, Francois Brisebois from Oppenheimer reiterated a Buy rating on Simulations Plus (SLP – Research Report), with a price target of $75.00. The company’s shares closed last Wednesday at $51.28.
According to TipRanks.com, Brisebois is ranked 0 out of 5 stars with an average return of -18.8% and a 25.0% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Tarsus Pharmaceuticals, and Avadel Pharmaceuticals.
Currently, the analyst consensus on Simulations Plus is a Moderate Buy with an average price target of $75.00.
Based on Simulations Plus’ latest earnings release for the quarter ending February 28, the company reported a quarterly revenue of $14.8 million and net profit of $4.41 million. In comparison, last year the company earned revenue of $13.15 million and had a net profit of $3.21 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.
Read More on SLP:
- H.C. Wainwright Thinks Gold Royalty’s Stock is Going to Recover
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clovis Oncology (CLVS), Veru (VERU) and Albireo Pharma (ALBO)
- Transaction in Own Shares
- Bed Bath & Beyond Stock Revives as Insiders up Their Stakes
- Needham Initiates a Buy Rating on Gitlab (GTLB)